Biomarkers in Neurodegenerative Diseases: Cortisol

Batista, Patrícia Serpa de Souza; Pereira, Anabela

doi:10.4172/2155-9929.1000277

Cited by 7 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As already mentioned, several neurodegenerative diseases involve glucocorticoid overdrive. In Alzheimer's disease, a chronic form of dementia caused by extracellular deposits of β-amyloid and intracellular tau hyperphosphorylation, there are increased levels of cortisol in the cerebrospinal fluid and dysregulation of the HPA axis [15][16][17]. In Parkinson's disease, the progressive loss of dopaminergic neurons of the substantia nigra is accompanied by higher diurnal cortisol levels and changes of the cortisol circadian rhythm [18].…”

Section: Introductionmentioning

confidence: 99%

“…Stroke causes hypercortisolemia plus decline in cognition, low levels of neurotrophic factors, and increased markers of oxidative stress [29,30]. Thus, the concomitant changes in the production, action, central regulation, and rhythm of glucocorticoids with changes of brain pathology have led to cortisol being proposed as a biomarker of human neurodegeneration [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases

Nicola

Meyer

Guennoun

et al. 2020

IJMS

View full text Add to dashboard Cite

Glucocorticoids are crucial for stress-coping, resilience, and adaptation. However, if the stress hormones become dysregulated, the vulnerability to stress-related diseases is enhanced. In this brief review, we discuss the role of glucocorticoids in the pathogenesis of neurodegenerative disorders in both human and animal models, and focus in particular on amyotrophic lateral sclerosis (ALS). For this purpose, we used the Wobbler animal model, which mimics much of the pathology of ALS including a dysfunctional hypothalamic–pituitary–adrenal axis. We discuss recent studies that demonstrated that the pathological cascade characteristic for motoneuron degeneration of ALS is mimicked in the genetically selected Wobbler mouse and can be attenuated by treatment with the selective glucocorticoid receptor antagonist (GRA) CORT113176. In long-term treatment (3 weeks) GRA attenuated progression of the behavioral, inflammatory, excitatory, and cell-death-signaling pathways while increasing the survival signal of serine–threonine kinase (pAkt). The action mechanism of the GRA may be either by interfering with GR deactivation or by restoring the balance between pro- and anti-inflammatory signaling pathways driven by the complementary mineralocorticoid receptor (MR)- and GR-mediated actions of corticosterone. Accordingly, GR antagonism may have clinical relevance for the treatment of neurodegenerative diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases

Nicola

Meyer

Guennoun

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In this way, it is required a tool to help doctors, epidemiologists, and researchers in the investigation of human diseases by confirming a diagnosus and following ailment movement, which may distinguish explicit remedial targets. 4 A biomarker is a research center estimation that recognizes a disease or mirrors the movement of an illness process 5 . Along these lines, improvement of biomarkers may quantify disease risk, presence, and progression is one of the principle objectives and challenges in explore of neurodegenerative diseases.…”

Section: Introductionmentioning

confidence: 99%

Mechanism and biomarkers for neurodegenerative diseases: A systematic review

Nandini¹,

Sonar²,

Hemalatha³

et al. 2020

IJN

View full text Add to dashboard Cite

Neurodegenerative disease such as Parkinson's disease (PD), Alzheimer's disease (AD), Multiple sclerosis (MS), Huntington's disease (HD) are characterized by progressive loss of cognitive function, dementia and problems with movement. Neuronal loss is associated with extra and intercellular accumulation of misfolding proteins, oxidative stress, free radical formation, mitochondrial dysfunction, disruption of neuronal golgi apparatus, impaired bioenergetics, dysfunction of neurotrophins. Biomarkers that might aid in the diagnosis of these devastating and globally important disease are urgently sought and required. Therefore, range of biomarkers are explained for neurodegenerative disease.

show abstract

“…Several studies explore how the dog‐mediated interactions may affect the daily variation in cortisol levels . Since cortisol is not just a measure used for stress evaluation, but is also a potential neurodegenerative disease biomarker, our aim was to evaluate whether AAT adapted to formal ROT could modify salivary cortisol levels in AD patients.…”

mentioning

confidence: 99%

Efficacy of animal‐assisted therapy adapted to reality orientation therapy: measurement of salivary cortisol

et al. 2019

View full text Add to dashboard Cite

Biomarkers in Neurodegenerative Diseases: Cortisol

Abstract: Neurodegenerative diseases are characterized by progressive loss of cognitive function, dementia, and problems with movements.

Cited by 7 publications

References 22 publications

Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases

Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases

Mechanism and biomarkers for neurodegenerative diseases: A systematic review

Efficacy of animal‐assisted therapy adapted to reality orientation therapy: measurement of salivary cortisol

Contact Info

Product

Resources

About